Jeremy D. Sanderson

Jeremy D. Sanderson

Auto-generated profile, based on publicly available information

Jeremy D. Sanderson

Guy’s and St Thomas’ Hospital, London, UK

Research Focus & Metrics

Academic Career Length

27Years (2000-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 September 2019 in Gut
Verified
Journal Article
Open access
CLChristopher Andrew Lamb
Christopher Andrew Lamb
NKNicholas Alexander Kennedy
Nicholas Alexander Kennedy
TRTim Raine
Tim Raine
PHPhilip Anthony Hendy
Philip Anthony Hendy
PSPhilip J Smith
Philip J Smith
AHA Barney Hawthorne
A Barney Hawthorne
Ulcerative colitis and Crohn’s disease are the principal forms of inflammatory bowel disease. Both represent chronic inflammation of the gastrointestinal tract, which displays heterogeneity in inflammatory and symptomatic burden between patients and within individuals over time. Optimal management relies on understanding and tailoring evidence-based interventions by clinicians in partnership with patients. This guideline for management of inflammatory bowel disease in adults over 16 years of age was developed by Stakeholders representing UK physicians (British Society of Gastroenterology), surgeons (Association of Coloproctology of Great Britain and Ireland), specialist nurses (Royal College of Nursing), paediatricians (British Society of Paediatric Gastroenterology, Hepatology and Nutrition), dietitians (British Dietetic Association), radiologists (British Society of Gastrointestinal and Abdominal Radiology), general practitioners (Primary Care Society for Gastroenterology) and patients (Crohn’s and Colitis UK). A systematic review of 88 247 publications and a Delphi consensus process involving 81 multidisciplinary clinicians and patients was undertaken to develop 168 evidence- and expert opinion-based recommendations for pharmacological, non-pharmacological and surgical interventions, as well as optimal service delivery in the management of both ulcerative colitis and Crohn’s disease. Comprehensive up-to-date guidance is provided regarding indications for, initiation and monitoring of immunosuppressive therapies, nutrition interventions, pre-, peri- and postoperative management, as well as structure and function of the multidisciplinary team and integration between primary and secondary care. Twenty research priorities to inform future clinical management are presented, alongside objective measurement of priority importance, determined by 2379 electronic survey responses from individuals living with ulcerative colitis and Crohn’s disease, including patients, their families and friends.

1 January 2011 in BMC Microbiology
Verified
Journal Article
Open access
PDF file
AWAlan W Walker
Alan W Walker
JSJeremy D Sanderson
Jeremy D Sanderson
CCCarol Churcher
Carol Churcher
GPGareth C Parkes
Gareth C Parkes
BHBarry N Hudspith
Barry N Hudspith
LPLiljana Petrovska
Liljana Petrovska
The gut microbiota is thought to play a key role in the development of the inflammatory bowel diseases Crohn's disease (CD) and ulcerative colitis (UC). Shifts in the composition of resident bacteria have been postulated to drive the chronic inflammation seen in both diseases (the "dysbiosis" hypothesis). We therefore specifically sought to compare the mucosa-associated microbiota from both inflamed and non-inflamed sites of the colon in CD and UC patients to that from non-IBD controls and to detect disease-specific profiles. Paired mucosal biopsies of inflamed and non-inflamed intestinal tissue from 6 CD (n = 12) and 6 UC (n = 12) patients were compared to biopsies from 5 healthy controls (n = 5) by in-depth sequencing of over 10,000 near full-length bacterial 16S rRNA genes. The results indicate that mucosal microbial diversity is reduced in IBD, particularly in CD, and that the species composition is disturbed. Firmicutes were reduced in IBD samples and there were concurrent increases in Bacteroidetes, and in CD only, Enterobacteriaceae. There were also significant differences in microbial community structure between inflamed and non-inflamed mucosal sites. However, these differences varied greatly between individuals, meaning there was no obvious bacterial signature that was positively associated with the inflamed gut. These results may support the hypothesis that the overall dysbiosis observed in inflammatory bowel disease patients relative to non-IBD controls might to some extent be a result of the disturbed gut environment rather than the direct cause of disease. Nonetheless, the observed shifts in microbiota composition may be important factors in disease maintenance and severity.

1 December 2014 in Research in Microbiology
Verified
Journal Article
Closed access
LHLesley Hoyles
Lesley Hoyles
AMAnne L. McCartney
Anne L. McCartney
HNHorst Neve
Horst Neve
GGGlenn R. Gibson
Glenn R. Gibson
JSJeremy D. Sanderson
Jeremy D. Sanderson
DSDouwe Sinderen
Douwe Sinderen

20 April 2018 in Microbiome
Verified
Journal Article
Open access
PDF file
LHLesley Hoyles
Lesley Hoyles
MJMaria L. Jiménez-Pranteda
Maria L. Jiménez-Pranteda
JCJulien Chilloux
Julien Chilloux
FBFrancois Brial
Francois Brial
Antonis MyridakisAntonis Myridakis
Antonis Myridakis
MDMarc-Emmanuel Dumas
Marc-Emmanuel Dumas
The dietary methylamines choline, carnitine, and phosphatidylcholine are used by the gut microbiota to produce a range of metabolites, including trimethylamine (TMA). However, little is known about the use of trimethylamine N-oxide (TMAO) by this consortium of microbes. A feeding study using deuterated TMAO in C57BL6/J mice demonstrated microbial conversion of TMAO to TMA, with uptake of TMA into the bloodstream and its conversion to TMAO. Microbial activity necessary to convert TMAO to TMA was suppressed in antibiotic-treated mice, with deuterated TMAO being taken up directly into the bloodstream. In batch-culture fermentation systems inoculated with human faeces, growth of Enterobacteriaceae was stimulated in the presence of TMAO. Human-derived faecal and caecal bacteria (n = 66 isolates) were screened on solid and liquid media for their ability to use TMAO, with metabolites in spent media analysed by 1H-NMR. As with the in vitro fermentation experiments, TMAO stimulated the growth of Enterobacteriaceae; these bacteria produced most TMA from TMAO. Caecal/small intestinal isolates of Escherichia coli produced more TMA from TMAO than their faecal counterparts. Lactic acid bacteria produced increased amounts of lactate when grown in the presence of TMAO but did not produce large amounts of TMA. Clostridia (sensu stricto), bifidobacteria, and coriobacteria were significantly correlated with TMA production in the mixed fermentation system but did not produce notable quantities of TMA from TMAO in pure culture. Reduction of TMAO by the gut microbiota (predominantly Enterobacteriaceae) to TMA followed by host uptake of TMA into the bloodstream from the intestine and its conversion back to TMAO by host hepatic enzymes is an example of metabolic retroconversion. TMAO influences microbial metabolism depending on isolation source and taxon of gut bacterium. Correlation of metabolomic and abundance data from mixed microbiota fermentation systems did not give a true picture of which members of the gut microbiota were responsible for converting TMAO to TMA; only by supplementing the study with pure culture work and additional metabolomics was it possible to increase our understanding of TMAO bioconversions by the human gut microbiota.

20 September 2008 in Alimentary Pharmacology & Therapeutics
Verified
Journal Article
Open access
PDF file
AAA. Ansari
A. Ansari
MAM. Arenas
M. Arenas
SGS. M. Greenfield
S. M. Greenfield
DMD. Morris
D. Morris
JLJ. Lindsay
J. Lindsay
JSJ. Sanderson
J. Sanderson
Summary: Background  One‐third of patients with inflammatory bowel disease (IBD) receiving azathioprine (AZA) withdraw treatment due to side effects or lack of clinical response.Aim  To investigate whether pharmacogenetic loci or metabolite concentrations explain clinical response or side effects to AZA.Methods  Patients with IBD were given 2 mg/kg of AZA without dose escalation or adjustment. Serial clinical response, thiopurine methyl transferase (TPMT) activity and thioguanine nucleotide (TGN) concentrations were measured over 6 months. All patients were genotyped for inosine triphosphatase (ITPase) and TPMT. Clinical response and side effects were compared to these variables.Results  Two hundred and seven patients were analysed. Thirty‐nine per cent withdrew due to adverse effects. Heterozygous TPMT genotype strongly predicted adverse effects (79% heterozygous vs. 35% wild‐type TPMT, P < 0.001). The ITPA 94C>A mutation was associated with withdrawal due to flu‐like symptoms (P = 0.014). A baseline TPMT activity below 35 pmol/h/mg/Hb was associated with a greater chance of clinical response compared with a TPMT above 35 pmol/h/mg/Hb (81% vs. 43% respectively, P < 0.001). Patients achieving a mean TGN level above 100 were significantly more likely to respond (P = 0.0017).Conclusions  TPMT testing predicts adverse effects and reduced chance of clinical response (TPMT >35 pmol/h/mg/Hb). ITPase deficiency is a predictor of adverse effects and TGN concentrations above 100 correlate with clinical response.

1 October 2011 in Inflammatory Bowel Diseases
Verified
Journal Article
Open access
PDF file
HCHelen Campbell
Helen Campbell
MEMichael Escudier
Michael Escudier
PPPritash Patel
Pritash Patel
CNCarlo Nunes
Carlo Nunes
TETimothy R. Elliott
Timothy R. Elliott
JSJeremy D. Sanderson
Jeremy D. Sanderson
Background. Orofacial granulomatosis (OFG) is a rare chronic inflammatory disease of unknown etiology sharing histological features with Crohn's disease (CD). T